Fri, Nov 28, 2014, 4:47 PM EST - U.S. Markets closed early today


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • insidetrack22 insidetrack22 Aug 5, 2013 3:40 PM Flag

    IMGN= Long term play

    The key to playing IMGN is to sit for the long haul. As Kadcyla's sales picks up, so well IMGN's revenue. However, IMGN's strength is that (1) its conjugate technology has been validated by the FDA and proven to work (Kadcyla aka. TdM-1) (2) IMGN's conjugate's platform can be utilized with many chemo agents to give it a boost via selective targeting. This equals more partnerships=more revenue (especially when chemos go generic and current company needs to turbo charge their current products to maintain market niche) (3) IMGN has its own pipline of products that is more lucrative than collecting royalties from joint ventures.
    There is just too many exciting news up ahead for IMGN to hang around in the $18's range. IMGN has already touched $20's, look for a series of positive news up ahead for a pop into the $20's. I personally like to play the IMGN options to limit any unexpected downside loss because IMGN management is famous for putting foot in mouth and dilution. However, if timed right, IMGN options can be very very lucrative.

10.29-0.06(-0.58%)Nov 28 1:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.